Ketamine for treatment-resistant unipolar depression: Current evidence

CNS Drugs

Volumn 26, Issue 3, 2012, Pages 189-204

  Mathew, Sanjay J ^a,b,c   Shah, Asim ^a   Lapidus, Kyle ^c   Clark, Crystal ^a,b   Jarun, Noor ^a   Ostermeyer, Britta ^a   Murrough, James W ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Depressive disorders; Glutamate receptor agonists; Ketamine; Major depressive disorder; NMDA receptor agonists.

Indexed keywords

GLUTAMATE RECEPTOR; GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RILUZOLE;

ARTICLE; CHRONIC PAIN; COGNITION; COMORBIDITY; COMPLEX REGIONAL PAIN SYNDROME; DISSOCIATIVE DISORDER; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REPEATED DRUG DOSE; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDAL IDEATION; SYMPTOM; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; COGNITION; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG ADMINISTRATION ROUTES; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; PAIN; SYNAPTIC TRANSMISSION;

EID: 84856818407     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11599770-000000000-00000     Document Type: Article

References (135)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163 (1): 28-40 (Pubitemid 43050100)
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163 (11): 1905-17 (Pubitemid 44807782)
3. Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for depression. Psych Services 2009; 60: 1439-45
4. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163 (7): 1161-72 (Pubitemid 44464443)
5. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163 (9): 1519-30 (Pubitemid 44465751)
6. Aanhet Rot M, Charney DS, Mathew SJ. Intravenous ketamine for treatment-resistant major depressive disorder. Primary Psychiatry 2008; 15 (4): 39-47 (Pubitemid 351556545)
7. Mathew SJ, Murrough J, Aanhet Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharm 2010; 13 (1): 71-82
8. Aanhet Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010; 67 (2): 139-45
9. Price RB, Nock MT, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66 (5): 522-6
10. Murrough JW, Mathew SJ. Overcoming antidepressant treatment resistance: focus on glutamate. In: Cryan JF, Leonard BE, editors. Depression: from psychopathology to pharmacotherapy. Basel: Karger, 2010: 89-100
11. Murrough JW, Perez AM, Mathew SJ, et al. A case of sustained remission following an acute course of ketamine in treatment-resistant depression [letter]. J Clin Psychiatry 2011; 72: 3
12. Shelton RC. Therapeutic options for treatment-resistant depression. CNS Drugs 2010; 24 (2): 131-61
13. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009; 70 (3): 387-96
14. Sackeim HA, Dillingham EM, Prudic J, et al. Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen Psychiary 2009; 66 (7): 729-37
15. Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology 2007; 32 (1): 244-54 (Pubitemid 44967804)
16. Sackeim HA, Brannan SK, Rush AJ, et al. Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol 2007; 10 (6): 817-26 (Pubitemid 350035822)
17. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010; 67 (5): 507-16
18. Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 2009; 34 (2): 522-34
19. Vialou V, Robison AJ, LaplantQC, et al.DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat Neurosci 2010; 13 (6): 745-52
20. Koo JW, Russo SJ, Ferguson D, et al. Nuclear factorkappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad SciUSA 2010; 107 (6): 2669-74
21. Mathew SJ. Treatment-resistant depression: recent developments and future directions. Depress Anxiety 2008; 25: 989-92
22. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008; 33 (9): 2080-92 (Pubitemid 351992096)
23. Abbott A. The drug deadlock. Nature 2010; 468: 158-9
24. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discovery 2008; 7 (5): 426-37 (Pubitemid 351619114)
25. Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009 Oct; 15 (5): 525-39
26. Price RB, Shungu DC, Mao X, et al. Amino acid neurotransmitter concentrations in anterior cingulate and occipital cortex in symptomatic patients with major depression: relationship to treatment resistance. Biol Psychiatry 2009; 65 (9): 792-800
27. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist:CP-101,606 in patientswith treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008; 28 (6): 631-7
28. ReichDL, SilvayG.Ketamine: an update on the first twentyfive years of clinical experience. Can J Anaesth 1989; 36 (2): 186-97 (Pubitemid 19110402)
29. Ketalar̈(ketamine) hydrochloride injection [package insert]. Rochester (MI): JHP Pharmaceuticals, LLC, 2009 Feb
30. Knox JW, Bovill JG, Clarke RS, et al. Clinical studies of induction agents: XXXVI. Ketamine. Br J Anaesth 1970; 42 (10): 875-85
31. Green SM, Johnson NE. Ketamine sedation for pediatric procedures: part 2, review and implications. Ann Emerg Med 1990; 19 (9): 1033-46 (Pubitemid 20275254)
32. Harrison NL, Simmonds MA. Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol 1985; 84 (2): 381-91 (Pubitemid 15169227)
33. Anis NA, Berry SC, Burton NR, et al. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by Nmethyl-aspartate. Br J Pharmacol 1983; 79 (2): 565-75 (Pubitemid 13055426)
34. Parsons CG, Quack G, Bresink I, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995; 34 (10): 1239-58
35. Cohen MG, Chan SL, Bhargava HN, et al. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol 1974; 23 (11): 1647-52
36. Lodge D, Anis NA, Burton NR. Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine. Neurosci Lett 1982; 29 (3): 281-6 (Pubitemid 12057304)
37. Weber M, Motin L, Gaul S, et al. Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons. Br J Pharmacol 2005; 144 (1): 98-107 (Pubitemid 40188551)
38. Volle RL, Alkadhi KA, Branisteanu DD, et al. Ketamine and ditran block end-plate ion conductance and [3H]phencyclidine binding to electric organ membrane. J Pharmacol Exp Ther 1982; 221 (3): 570-6 (Pubitemid 12085876)
39. Hirota K, Hashimoto Y, Lambert DG. Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in Chinese hamster ovary cells. Anesth Analg 2002; 95 (6): 1607-10 (Pubitemid 35423948)
40. Morita T, Hitomi S, Saito S, et al. Repeated ketamine administration produces up-regulation of muscarinic acetylcholine receptors in the forebrain, and reduces behavioral sensitivity to scopolamine in mice. Psychopharmacology (Berl) 1995; 117 (4): 396-402
41. Bevan RK, Rose MA, Duggan KA. Evidence for direct interaction of ketamine with alpha 1-and beta 2-adrenoceptors. Clin Exp Pharmacol Physiol 1997; 24 (12): 923-6 (Pubitemid 27494300)
42. Smith DJ, Pekoe GM, Martin LL, et al. The interaction of ketamine with the opiate receptor. Life Sci 1980; 26 (10): 789-95 (Pubitemid 10071078)
43. Smith DJ, Bouchal RL, deSanctis CA, et al. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 1987; 26 (9): 1253-60 (Pubitemid 17154877)
44. Smith DJ, Azzaro AJ, Zaldivar SB, et al. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology 1981; 20 (4): 391-6 (Pubitemid 11143399)
45. Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl- cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001; 306 (1-2): 81-4 (Pubitemid 32524303)
46. Appadu BL, Lambert DG. Interaction of i.v. anaesthetic agents with 5-HT3 receptors. Br J Anaesth 1996; 76 (2): 271-3 (Pubitemid 26043460)
47. Barann M, Gothert M, Fink K, et al. Inhibition by anaesthetics of 14C-guanidinium flux through the voltage-gated sodium channel and the cation channel of the 5-HT3 receptor of N1E-115 neuroblastoma cells. Naunyn Schmiedebergs Arch Pharmacol 1993; 347 (2): 125-32 (Pubitemid 23068162)
48. Seeman P, Guan HC, Hirbec H. Dopamine D2high receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse 2009; 63 (8): 698-704
49. Seeman P, Ko K, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 2005; 10 (9): 877-83 (Pubitemid 43080122)
50. Micheletti G, Lannes B, Haby C, et al. Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum. Brain Res Mol Brain Res 1992; 14 (4): 363-8
51. Jordan S, Chen R, Fernalld R, et al. In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors. Eur J Pharmacol 2006; 540 (1-3): 53-6 (Pubitemid 43866700)
52. Aalto S, Hirvonen J, Kajander J, et al. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl) 2002; 164 (4): 401-6 (Pubitemid 35435716)
53. Momosaki S, Hatano K, Kawasumi Y, et al. Rat-PET study without anesthesia: anesthetics modify the dopamine D1 receptor binding in rat brain. Synapse 2004; 54 (4): 207-13 (Pubitemid 39532061)
54. Salmi E, Langsjo JW, Aalto S, et al. Subanesthetic ketamine does not affect 11C-flumazenil binding in humans. Anesth Analg 2005; 101 (3): 722-5 (Pubitemid 41208501)
55. Heinzel A, Steinke R, Poeppel TD, et al. S-ketamine and GABA-A-receptor interaction in humans: an exploratory study with I-123-iomazenil SPECT. Hum Psychopharmacol 2008; 23 (7): 549-54
56. Lin LH, Chen LL, Zirrolli JA, et al. General anesthetics potentiate gamma-aminobutyric acid actions on gammaaminobutyric acidA receptors expressed by Xenopus oocytes: lack of involvement of intracellular calcium. J Pharmacol Exp Ther 1992; 263 (2): 569-78
57. Allaoua H, Chicheportiche R. Anaesthetic properties of phencyclidine (PCP) and analogues may be related to their interaction with Na+ channels. Eur J Pharmacol 1989; 163 (2-3): 327-35 (Pubitemid 19126298)
58. Chen XS, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci 2009; 29 (3): 600-9
59. Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)-and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997; 7 (1): 25-38 (Pubitemid 27139717)
60. Paul R, Schaaff N, Padberg F, et al. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 2009; 10 (3): 241-4
61. Finck AD, Ngai SH. Opiate receptor mediation of ketamine analgesia. Anesthesiology 1982; 56 (4): 291-7 (Pubitemid 12135766)
62. Pfenninger E, Baier C, Claus S, et al. Psychometric changes as well as analgesic action and cardiovascular adverse effects of ketamine racemate versus s-(+)-ketamine in subanesthetic doses [in German]. Anaesthesist 1994; 43 (2): 68-75
63. Himmelseher S, Pfenninger E. The clinical use of S-(+)-ketamine: a determination of its place. Anasthesiol Intensivmed Notfallmed Schmerzther 1998; 33 (12): 764-70
64. Langsjo J, Maksimow A, Salmi E, et al. S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology 2005; 103: 258-68 (Pubitemid 41076722)
65. Piper SN, Beschmann R, Mengistu A, et al. Postoperative analgosedation with S(+)-ketamine decreases the incidences of postanesthetic shivering and nausea and vomiting after cardiac surgery. Med Sci Monit 2008; 14 (12): 159-65
66. Proescholdt M, Heimann A, Kempski O. Neuroprotection of S(+) ketamine isomer in global forebrain ischemia. Brain Res 2001; 904: 245-51 (Pubitemid 32537648)
67. Pfenninger E, Durieux M, Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology 2002; 96 (2): 357-66 (Pubitemid 34121746)
68. Blonk M, Koder BG, van den Bemt PM, et al. Use of oral ketamine in chronic pain management: a review. Eur J Pain 2010; 14 (5): 466-72
69. Abrams R, Morrison JE, Villasenor A, et al. Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesth Prog 1993; 40 (3): 63-6 (Pubitemid 24185466)
70. Weksler N, Ovadia L, Muati G, et al. Nasal ketamine for paediatric premedication. Can J Anaesth 1993; 40 (2): 119-21 (Pubitemid 23094711)
71. Louon A, Reddy VG. Nasal midazolam and ketamine for paediatric sedation during computerised tomography. Acta Anaesthesiol Scand 1994; 38 (3): 259-61 (Pubitemid 24133395)
72. Diaz JH. Intranasal ketamine preinduction of paediatric outpatients. Paediatr Anaesth 1997; 7 (4): 273-8 (Pubitemid 27304686)
73. Weber FH, Wulf H, el Saeidi G. Premedication with nasal s-ketamine and midazolam provides good conditions for induction of anesthesia in preschool children. Can J Anaesth 2003; 50 (5): 470-5 (Pubitemid 36833603)
74. Roelofse JA, Shipton EA, de la Harpe CJ, et al. Intranasal sufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in the pediatric population prior to undergoing multiple dental extractions under general anesthesia: a prospective, double-blind, randomized comparison. Anesth Prog 2004; 51 (4): 114-21
75. Kaube H, Herzog J, Ka?ufer T, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000; 55 (1): 139-41 (Pubitemid 30461018)
76. Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 2004; 108 (1-2): 17-27 (Pubitemid 38251669)
77. Huge V, Lauchart M, Magerl W, et al. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain 2010; 14 (4): 387-94
78. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47 (4): 351-4 (Pubitemid 30109248)
79. White PF, WayWL, Trevor AJ. Ketamine: its pharmacology and therapeutic uses. Anesthesiology 1982; 56 (2): 119-36 (Pubitemid 12164876)
80. Noppers I, Niesters M, Aarts L, et al. Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother 2010; 11 (14): 2417-29
81. Subramanian K, Subramanian B, Steinbrook RA. Ketamine as adjunct analgesic to opiates: a quantitative and qualitative systematic review. Anesth Analg 2004; 99: 482-95 (Pubitemid 38970424)
82. Bell RF, Dahl JB, Moore RA, et al. Perioperative ketamine for acute postoperative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand 2005; 49: 1405-28 (Pubitemid 41565020)
83. McQueen A, Baroletti S. Adjuvant ketamine analgesia for the management of cancer pain. Ann Pharmacother 2002; 36: 1614-9
84. Hocking G, Cousins M. Ketamine in chronic pain management: an evidence-based review. Anesth Analges 2003; 97: 1730-9 (Pubitemid 37475130)
85. Correll GE, Maleki J, Gracely EJ, et al. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med 2004; 5 (3): 263-75 (Pubitemid 39369246)
86. Goldberg ME, Domsky R, Scaringe D, et al. Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome. Pain Physician 2005; 8 (2): 175-9 (Pubitemid 40691829)
87. Schwartzman RJ, Alexander GM, Grothusen JR, et al. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 2009; 147: 107-15
88. Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 2006; 63 (8): 856-64 (Pubitemid 44188478)
89. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-Daspartate receptor antagonists. Arch Gen Psychiatry 2000; 57 (3): 270-6 (Pubitemid 30140436)
90. Zarate Jr CA, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161 (1): 171-4 (Pubitemid 38419327)
91. Zarate Jr CA, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57 (4): 430-2 (Pubitemid 40215774)
92. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61: 822-5 (Pubitemid 46330247)
93. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-Daspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35 (4): 1155-9
94. Glue P, Gulati A, Le Nedelec M, et al. Dose-and exposureresponse to ketamine in depression. Biol Psychiatry 2011; 70 (4): e9-10
95. Murrough JW, Gallo JM, Collins KA, et al. Reply to: doseand exposure-response to ketamine in depression. Biol Psychiatry 2011; 70 (4): e11-2
96. Nock MK, BanajiMR. Assessment of self-injurious thoughts using a behavioral test. Am J Psychiatry 2007; 164: 820-3 (Pubitemid 46808538)
97. Diaz Granados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71 (12): 1605-11
98. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharm 2011; 14 (8): 1127-31
99. Thangathurai D, Mogos M. Ketamine alleviates fear, depression, and suicidal ideation in terminally ill patients [letter]. J Palliat Med 2011; 14 (4): 389
100. Curran HV, Monaghan L. In and out of the K-hole: a comparison of the acute residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001; 96: 749-60 (Pubitemid 32458712)
101. Morgan CJA, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2009; 105: 121-33
102. Rowland LM, Astur RS, Jung RE, et al. Selective cognitive impairments associated withNMDAreceptor blockade in humans. Neuropsychopharmacology 2005; 30: 633-9 (Pubitemid 40271165)
103. Morgan CJA, Mofeez A, Brandner B, et al. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study. Psychopharmacology 2004; 172: 298-308 (Pubitemid 38392323)
104. Malhotra AK, Pinals DA, Weingarter H, et al. NMDA receptor function and human cognition: the effects of ketamine and healthy volunteers. Neuropsychopharmacology 1996; 14: 301-7 (Pubitemid 26151927)
105. Hetem LA, Danion JM, Diemunsch P, et al. Effect of subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (Berl) 2000; 152: 283-8
106. Curran HV, Morgan CJA. Cognitive, dissociative and psychogenetic effects of ketamine on recreational users on the night of drug use and three days later. Addiction 2000; 95: 575-90
107. Jevtovic-Todorovic V, Wozniak D, Bemshoff N, et al. A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res 2001; 895: 264-7 (Pubitemid 32231166)
108. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacol (Berl) 2006; 188 (4): 408-24 (Pubitemid 46758974)
109. Morgan CJ, Monaghan L, Curran HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 2004; 99 (11): 1450-61 (Pubitemid 39490532)
110. Olney JW, Labruyere J, Wang G, et al. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991; 254 (5037): 1515-8 (Pubitemid 21917493)
111. Phillips ML, Drevets WC, Rauch SL, et al. Neurobiology of emotion perception I: the neural basis of normal emotion perception. Biol Psychiatry 2003; 54 (5): 504-14 (Pubitemid 37289437)
112. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010; 35 (1): 192-216
113. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 2010; 167 (11): 1305-20
114. Murrough JW, Iacoviello B, Neumeister A, et al. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem2011; 96 (4): 553-63
115. Erk S, Mikschl A, Stier S, et al. Acute and sustained effects of cognitive emotion regulation in major depression. J Neurosci 2010; 30 (47): 15726-34
116. Vollenweider FX, Leenders KL, Scharfetter C, et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997; 7 (1): 9-24 (Pubitemid 27139716)
117. Breier A, Malhotra AK, Pinals DA, et al. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154 (6): 805-11 (Pubitemid 27230103)
118. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010; 11 (9): 642-51
119. Kennedy SH, Evans KR, Kruger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001; 158 (6): 899-905 (Pubitemid 32547619)
120. Breier A, Adler CM, Weisenfeld N, et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 1998; 29 (2): 142-7 (Pubitemid 28221792)
121. Abel KM, Allin MP, Kucharska-Pietura K, et al. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 2003; 14 (3): 387-91 (Pubitemid 36337936)
122. Abel KM, Allin MP, Kucharska-Pietura K, et al. Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state. Hum Brain Mapp 2003; 18 (2): 135-45 (Pubitemid 36150933)
123. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004; 61 (9): 877-89 (Pubitemid 39181077)
124. Salvadore G, Cornwell BR, Colon-Rosario V, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009; 65 (4): 289-95
125. Salvadore G, Cornwell BR, Sambataro F et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010; 35 (7): 1415-22
126. Davidson RJ, Irwin W, Anderle MJ, et al. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003; 160 (1): 64-75 (Pubitemid 36042428)
127. Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011; 36 (1): 183-206
128. Kennedy SH, Giacobbe P, Rizvi SJ, et al. Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry 2011; 168 (5): 502-10
129. Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 2011; 191 (2): 122-7
130. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329 (5994): 959-64
131. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. BioPsychiatry 2006 Jun 15; 59 (12): 1116-27
132. Murrough JW, Charney DS. Cracking the moody brain: lifting the mood with ketamine. Nat Med 2010; 16 (12): 1384-5
133. Maeng S, Zarate Jr CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63 (4): 349-52 (Pubitemid 351146651)
134. Correll GE, Futter GE. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 2006; 7 (1): 92-5 (Pubitemid 43337717)
135. Liebrenz M, Stohler R, Borgeat A. Repeated intravenous ketamine therapy in a patientwith treatment-resistantmajor depression.World J Biol Psychiatry 2009; 10 (4 Pt 2): 640-3